Nuvation Bio Stock Forecast, Price & News

+0.84 (+7.86 %)
(As of 04/14/2021 03:59 PM ET)
Today's Range
Now: $11.53
50-Day Range
MA: $11.50
52-Week Range
Now: $11.53
Volume27,175 shs
Average Volume821,973 shs
Market Capitalization$2.51 billion
P/E RatioN/A
Dividend YieldN/A
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting CDK2, CDK4, and CDK6. It is also developing NUV-868, a selective inhibitor of the BET family of epigenetic transcriptional regulators; NUV-569, a differentiated selective inhibitor of the Wee1 kinase; NUV-1182, an adenosine receptor inhibitor; and DDC platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to androgen receptor-expressing cancer cells , as well as PARP inhibitor to ER-expressing cancer cells. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was incorporated in 2018 and is headquartered in New York, New York.
Nuvation Bio logo

Industry, Sector and Symbol

Industry Biotechnology
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$2.51 billion
Next Earnings Date6/10/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

2.23 out of 5 stars

Medical Sector

93rd out of 2,019 stocks

Biotechnology Industry

9th out of 145 stocks

Analyst Opinion: 4.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
+0.84 (+7.86 %)
(As of 04/14/2021 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NUVB News and Ratings via Email

Sign-up to receive the latest news and ratings for NUVB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Nuvation Bio (NYSE:NUVB) Frequently Asked Questions

Is Nuvation Bio a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nuvation Bio in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Nuvation Bio stock.
View analyst ratings for Nuvation Bio
or view top-rated stocks.

What stocks does MarketBeat like better than Nuvation Bio?

Wall Street analysts have given Nuvation Bio a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nuvation Bio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Nuvation Bio's next earnings date?

Nuvation Bio is scheduled to release its next quarterly earnings announcement on Thursday, June 10th 2021.
View our earnings forecast for Nuvation Bio

What price target have analysts set for NUVB?

6 brokers have issued 12-month price targets for Nuvation Bio's shares. Their forecasts range from $15.00 to $20.00. On average, they expect Nuvation Bio's stock price to reach $17.40 in the next twelve months. This suggests a possible upside of 50.9% from the stock's current price.
View analysts' price targets for Nuvation Bio
or view top-rated stocks among Wall Street analysts.

Who are Nuvation Bio's key executives?

Nuvation Bio's management team includes the following people:
  • Dr. David T. Hung M.D., Founder, Pres, CEO & Director (Age 63, Pay $1.16M)
  • Ms. Jennifer A. Fox, Chief Financial Officer (Age 49, Pay $557.9k)
  • Dr. Gary Hattersley, Chief Scientific Officer (Age 54, Pay $687.88k)
  • Ms. Stacy Markel, Sr. VP of HR (Age 56)
  • Dr. Thomas S. Templeman, Sr. VP of Pharmaceutical Operations & Quality (Age 61)
  • Dr. Sergey Yurasov, Chief Medical Officer (Age 52)
  • Dr. Lisa V. DeLuca, Sr. VP of Regulatory Affairs
  • Kenneth Guernsey, Sec.

Who are some of Nuvation Bio's key competitors?

What is Nuvation Bio's stock symbol?

Nuvation Bio trades on the New York Stock Exchange (NYSE) under the ticker symbol "NUVB."

How do I buy shares of Nuvation Bio?

Shares of NUVB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nuvation Bio's stock price today?

One share of NUVB stock can currently be purchased for approximately $11.53.

How much money does Nuvation Bio make?

Nuvation Bio has a market capitalization of $2.51 billion.

How many employees does Nuvation Bio have?

Nuvation Bio employs 36 workers across the globe.

What is Nuvation Bio's official website?

The official website for Nuvation Bio is www.nuvationbio.com.

How can I contact Nuvation Bio?

The company can be reached via phone at 650-245-3818.

This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.